Cardiovascular Disease

Change in HbA1c is likely the greatest mediator of the effect of the GLP-1 receptor agonist liraglutide on cardiovascular disease for adults with poorly controlled type 2 diabetes who are at high CV risk, according to findings from an exploratory analysis of the LEADER trial published in Diabetes Care.

Between 1999 and 2017, rural areas experienced a greater prevalence of age-adjusted CV mortality compared with metropolitan areas, regardless of subgroup, researchers reported.

Treatment with biologic DMARDs in patients with rheumatoid arthritis was associated with a reduced risk for cardiovascular disease, as well as protective calcification of noncalcified lesions and a lower likelihood of new plaque formation, according to data published in Arthritis & Rheumatology.

People with an adverse childhood family environment had elevated risk for CVD and all-cause mortality at middle age, according to a study published in the Journal of the American Heart Association.

Higher alcohol consumption predicted by genetics was associated with elevated risk for peripheral artery disease and stroke, according to a study published in Circulation: Genomic and Precision Medicine.

Once the COVID-19 pandemic starts to subside, gradual reintroduction and collaborative approaches are important to continue the care of patients with untreated CVD, according to guidance from 15 North American cardiology societies.

Patients with chronic diseases aged older than 65 years, particularly those with cardiovascular disease or diabetes, are at significantly greater risk for acquiring COVID-19 and subsequent mortality from the virus, according to findings presented during a CDC webinar.

People with type 2 diabetes are experiencing fewer cardiovascular complications today compared with 1990s data; however, greater all-cause mortality persists among those with diabetes compared with those without the disease, according to a longitudinal analysis of Australian adults published in The Journal of Clinical Endocrinology & Metabolism.

Among a large cohort of transgender adults prescribed gender-affirming hormones, higher levels of cross-sex hormones did not increase the odds of hypertension, and hypertension diagnoses were fewer among transgender women who were ever prescribed progestins, according to data published in Transgender Health.

Higher socioeconomic status had been widely regarded to garner better psychological and CV health, but a recent analysis demonstrated that upwardly mobile individuals who achieve greater income than their parents may have adverse cardiometabolic health, more in line with disadvantaged people than consistently advantaged people.